MX2023000033A - Arimoclomol para tratar la enfermedad de gaucher. - Google Patents

Arimoclomol para tratar la enfermedad de gaucher.

Info

Publication number
MX2023000033A
MX2023000033A MX2023000033A MX2023000033A MX2023000033A MX 2023000033 A MX2023000033 A MX 2023000033A MX 2023000033 A MX2023000033 A MX 2023000033A MX 2023000033 A MX2023000033 A MX 2023000033A MX 2023000033 A MX2023000033 A MX 2023000033A
Authority
MX
Mexico
Prior art keywords
arimoclomol
disease
treat gaucher
gaucher
treat
Prior art date
Application number
MX2023000033A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Kirkegaard Jensen
Linda Ingemann
Christine Í Dali
Hinsby Anders Mørkeberg
Cathrine Kolster Fog-Tønnesen
Original Assignee
Kempharm Denmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Denmark As filed Critical Kempharm Denmark As
Publication of MX2023000033A publication Critical patent/MX2023000033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023000033A 2020-06-24 2021-06-24 Arimoclomol para tratar la enfermedad de gaucher. MX2023000033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20182067 2020-06-24
PCT/EP2021/067366 WO2021260120A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Publications (1)

Publication Number Publication Date
MX2023000033A true MX2023000033A (es) 2023-04-10

Family

ID=71143584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000033A MX2023000033A (es) 2020-06-24 2021-06-24 Arimoclomol para tratar la enfermedad de gaucher.

Country Status (14)

Country Link
US (1) US20230226036A1 (enExample)
EP (1) EP4171559B1 (enExample)
JP (2) JP2023531750A (enExample)
KR (1) KR20230035586A (enExample)
CN (1) CN116075305A (enExample)
AU (1) AU2021295437A1 (enExample)
BR (1) BR112022026396A2 (enExample)
CA (1) CA3183559A1 (enExample)
DK (1) DK4171559T3 (enExample)
ES (1) ES3056005T3 (enExample)
IL (1) IL299250A (enExample)
MX (1) MX2023000033A (enExample)
PT (1) PT4171559T (enExample)
WO (1) WO2021260120A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013125923A (ru) * 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
EP2484371B1 (en) * 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
NZ623910A (en) * 2009-07-28 2016-06-24 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
SI3448382T1 (sl) * 2016-04-29 2021-03-31 Orphazyme A/S, c/o COBIS A/S Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
EP4171559A1 (en) 2023-05-03
US20230226036A1 (en) 2023-07-20
WO2021260120A1 (en) 2021-12-30
JP2023531750A (ja) 2023-07-25
DK4171559T3 (da) 2025-12-15
CN116075305A (zh) 2023-05-05
KR20230035586A (ko) 2023-03-14
EP4171559B1 (en) 2025-09-10
JP2026042936A (ja) 2026-03-11
ES3056005T3 (en) 2026-02-17
CA3183559A1 (en) 2021-12-30
PT4171559T (pt) 2025-12-16
IL299250A (en) 2023-02-01
BR112022026396A2 (pt) 2023-03-14
JP7849574B2 (ja) 2026-04-21
AU2021295437A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
MX2022010011A (es) Inhibidores de prmt5 novedosos.
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BR0009043A (pt) Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
MX2021014315A (es) Compuestos derivados de 1,3,4-oxadiazol homoftalimida como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2023007551A (es) Arimoclomol para el tratamiento de la enfermedad de niemann pick, tipo c, en pacientes con mutaciones de sentido erroneo de tipo reticulo endoplasmatico (er).
MX2024009444A (es) Métodos de tratamiento para la fibrosis quística
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
EA199800721A1 (ru) Ингибитор реваскуляризации
BR112018076800A2 (pt) derivado de guanidina, medicamento, inibidor da proteína 1 da translocação de linfoma de tecido linfóide associado com mucosa, e, agente terapêutico ou profilático.
CY1123717T1 (el) Αριμοκλομολη για την αγωγη διαταραχων που σχετιζονται με γλυκοκερεβροσιδαση
EP1192949A4 (en) PREVENTIVE OR THERAPEUTIC DRUGS FOR TREATING FIBROSIS AND CONTAINING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS
JOP20250121A1 (ar) مشتقات ٢-أمينو-n-(٤-أمينو-٣، ٤-ديوكسو-١-(٢-أوكسو بيروليدين-٣-يل)بيوتان-2-يل)بنزاميد كمثبطات بروتياز لعلاج أو الوقاية من عدوي فيروس كورونا
BRPI0414777A (pt) compostos, composições farmacêuticas, uso de um ou mais compostos, e, método de tratar um paciente que sofre de um distúrbio
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
BR112023018932A2 (pt) Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular
ATE384529T1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
RU99121654A (ru) Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
BR112022026396A2 (pt) Arimoclomol para o tratamento da doença de gaucher
BR112022011344A2 (pt) Compostos para tratamento de doença de alzheimer e uso desses compostos
RU2007137115A (ru) Новые офтальмологические композиции и способы их применения
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
US11376280B2 (en) Treating rotator cuff conditions